Samsung Biologics: geographic diversification is a sound business decision

South Korean declaration improvement and manufacturing organisation (CDMO) Samsung Biologics has been connected a steep upward maturation trajectory since receiving its archetypal licence to nutrient biologic cause substances successful 2015.

That FDA support was followed successful 2016 by a Certificate of Good Manufacturing Practice (GMP) compliance from the EMA for biologics cause substance and cause product, and the institution present has implicit 450 approvals from regulators astir the world. The enlargement of Samsung's manufacturing licences is mirrored successful the maturation of its performance, which saw it execute revenues of $3.1bn (Won4,557bn) successful 2025, a 30% summation from the erstwhile year.

Until now, that enactment has been centred connected the Songdo Bio Cluster successful the South Korean metropolis of Incheon, wherever Samsung volition person 3 campuses, having precocious acquired onshore for Bio Campus III, which volition beryllium acceptable speech for aboriginal modalities including enactment connected compartment and cistron therapies and vaccines. The clump volition besides beryllium the determination for Samsung's forthcoming unfastened innovation centre, which is owed to unfastened successful 2027 and is being built successful concern with Lilly Gateway Labs. But a cardinal portion of the company's plans for continued maturation involves adding capableness extracurricular its location country.

On 20 July 2026, Samsung unveiled its plans for the $1.8bn (SFr1.46bn) acquisition of PolyPeptide Group, which specialises successful peptide-based progressive pharmaceutical ingredients (APIs) and produces 1 3rd of the commercially approved peptides successful the world. In summation to expanding Samsung's capabilities beyond antibodies and ADCs and into peptide therapeutics, including GLP-1s, its woody with the Swiss CDMO besides comes with a web of sites crossed Sweden, Belgium, France, the US, and India, unneurotic with a firm bureau successful Switzerland and an innovation centre successful Strasbourg, France.

The PolyPeptide woody is expected to adjacent earlier the extremity of 2026, erstwhile it volition physique connected Samsung's archetypal large M&A transaction of the year. That saw the South Korean CDMO implicit its $280M acquisition of GSK's Rockville, MD, US installation connected March 31, 2026. The statement gave Samsung its archetypal US manufacturing beingness and an further 60,000L of cause substance capacity, expanding its planetary capableness to 845,000L.

Samsung Biologic's maturation strategy

Speaking to Pharmaceutical Technology astatine the 2026 BIO International Convention (BIO 2026) successful San Diego, California, successful June 2026, James Choi, enforcement vice president, main selling serviceman and caput of income support, task management, and planetary nationalist affairs, discussed Samsung's maturation strategy, the request for a divers proviso chain, and however the caller Maryland installation fits into those plans.